Global Epinephrine Autoinjector Market - 2022-2029

Market Overview

Epinephrine Autoinjector Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Epinephrine (adrenaline) is a medicine used to treat conditions such as asthma, cardiac arrest, superficial bleeding, and anaphylaxis. It can also be used by inhalation for croup. Epinephrine autoinjectors are hand-held devices carried by those with severe allergies; the epinephrine delivered by the device is an emergency treatment for an anaphylactic reaction. Epinephrine autoinjector is also called EpiPen; a device used to inject a measured dose of adrenaline by autoinjector technology. The device is capable of intramuscular injection for instant and better results. The pen is designed specifically to avoid accidental punctures in the skin, as the syringe is enclosed under a protected shield and needs to operate manually to inject when kept on the patient's skin. The global Epinephrine Autoinjector Market growth is driven by several factors, such growing prevalence of allergies and their awareness among customers, increasing advancement in the product with cost-effective solutions, and rising demand for autoinjectors instead of traditional syringes.

Market Dynamics: Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.

Anaphylaxis is a severe allergic reaction to the venom, food, or medication. Mostly it is caused by a bee sting or eating foods that are known to cause allergies, such as peanuts or tree nuts. Common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex. When anaphylaxis is suspected, epinephrine solution is given as soon as possible as an intramuscular injection in the middle of the outer side of the thigh, which corresponds to the location of the vast us lateral muscle. According to the national library of medicine, between 1.6% and 5.1% of US citizens are estimated to have experienced anaphylaxis. Clinical databases such as PubMed have captured the growing prevalence of anaphylaxis. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it is the first-aid treatment option, thereby driving the global market. Ease of usage and disposal of drug injectors has created opportunities for autoinjectors. This, in turn, is boosting the market's growth.

However, multiple alternatives for injections and continuous advancements are expected to hamper the market growth.

Market Segmentation: The 0.3mg epinephrine auto-injector segment is projected to be the dominant segment in the market during the forecast period.

Based on dosage, the market is segmented into 0.15mg epinephrine auto-injector, 0.3mg epinephrine auto-injector, and 0.5mg epinephrine auto-injector.

The 0.3mg epinephrine auto-injector accounted for the largest market share due to its various applications across all age groups and moderate doses, among others. The growth of this segment is expected to have an exponential rise during the forecast period. The National Institute of Allergy and Infectious Diseases guidelines recommend epinephrine as a first-line treatment option. The prevalence of food allergies is high in children. Various studies have shown the majority of food allergy incidences, including anaphylaxis, occur in schools or daycare centres. Hence, epinephrine auto-injectors are considered an integral part of emergency care in schools and daycare centres.

The rising incidence of anaphylaxis in the adults & elderly is a primary factor driving the growth of the 0.5mg epinephrine auto-injector dose segment. Epinephrine is considered the first-line treatment for anaphylaxis. In addition, market players are focusing on providing generic, low-cost products. This is raising the demand for affordable treatment options for managing anaphylactic reactions.

Based on Age Group, the age group 6-12 years segment is expected to held significant market share in the fastest CAGR over the forecast period.

The age group 6-12 years children are more prone to anaphylaxis and are currently experiencing the leading position in the market and are expected to grow significantly in the forecast period. However, the prevalence of anaphylaxis is increasing in the geriatric population and is expected to grow at a considerable pace. The burden of anaphylaxis among children is growing, which requires quick and effective management. The government and regulatory bodies are giving safeguards to prevent fatal reactions among children in the 6-12 years of age group. The epinephrine, through auto-injectors, acts fast and can rapidly treat the most dangerous symptoms in children. Thus, it has always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions. Therefore, this is driving the segment growth.

Geographical Penetration: North America is the dominating region during the forecast period.

North America accounted for the largest market share of the global epinephrine autoinjector market in 2021. Several epinephrine autoinjectors are now available in the region. There are generic versions as well. Each contains the drug epinephrine. But, each device possesses its own unique set of instructions for use. Understanding the differences are essential to get the device one wants and knowing how to use it properly. Children with severe allergies now have access to a new generic version of EpiPen and EpiPen Jr. Epinephrine autoinjectors in the region. In August 2022, Sanofi Announces FDA Approval for its first voice-guided Epinephrine Auto-injector for Patients with Life-threatening Allergies named, Auvi-Q. The company has licensed the North American commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world.

Competitive Landscape:

Some of the major players in the global epinephrine autoinjector market include ALK-Abello A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players are involved in developing cost-effective and robust solutions to gain market share. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Epinephrine Autoinjector Market globally. In February 2022, Sanofi completed the acquisition of Amunix. This acquisition provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next-generation Conditionally Activated Biologics. Also, this acquisition adds a promising pipeline of T-cell engagers and cytokine therapies. In January 2022, Amneal acquired Saol Therapeutics' Baclofen Franchise, a private specialty pharmaceutical company. The acquisition expands Amneal's commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market.

COVID-19 Impact: Negative impact on the global epinephrine autoinjector market.

COVID-19 affects the global economy by directly affecting production and demand, disturbing the supply chain and market disruption, and having a financial impact on firms and financial markets. Most countries have relaxed lockdown regulations, but people are reluctant to visit doctors in person due to the fear of spreading coronavirus (COVID-19). Thus, companies in the epinephrine autoinjector market are adopting telemedicine as individuals prefer remote healthcare services during the COVID-19 era. The demand for telehealth technology will rise dramatically during the forecast period.

The global epinephrine autoinjector market report would provide an access to approximately 64 market data tables, 53 figures and 170 pages